Right now, stocks in companies developing a vaccine against the virus look very attractive to investors.
Is Moderna's stock too cheap to pass up? Â Today, however, it faces new challenges.
As a group, equities research analysts expect that Moderna, Inc.
Langer Independent Non-Executive Director Stephen A.
The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.
Puedes cambiar tus opciones en todo momento visitando.